Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07836530 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma

Name: Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma — clinical trial record (NCT07836530)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorBeOne Medicines

Started2026-10

View on ClinicalTrials.gov ↗

BeOne Medicines

59 trials monitored

See 7 trials at risk

Liver Cancer

1,505 trials monitored

See 60 trials at risk

The goal of this clinical trial is to learn how well BGB-B2033 works and how safe it is in people with hepatocellular carcinoma (HCC) who have previously received up to two treatments that included programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) medicines. Researchers will compare BGB-B2033 with either sorafenib or lenvatinib chosen by the study doctor to see which treatment works better and is safer. The main questions it aims to answer are: * Does BGB-B2033 help control or slow the growth of liver cancer? * What medical problems or side effects do participants have while taking BGB-B2033? * Does BGB-B2033 help to prolong the survival for liver cancer participants over Lenvatinib/sorafenib?

Trial Details

NCT Number	NCT07836530
Lead Sponsor	BeOne Medicines
Conditions	Hepatocellular Carcinoma, Liver Cancer
Enrollment	492 participants
Start Date	2026-10
Primary Completion	2029-09-21 (estimated)
Study Completion	2030-06-21 (estimated)
Updated on ClinicalTrials.gov	2026-09-23